Market Overview:
The global atherosclerosis drug market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of atherosclerosis, rising geriatric population, and technological advancements in the field of atherosclerosis drugs. The anti-platelet medications segment is expected to dominate the global atherosclerosis drug market during the forecast period owing to its high usage for preventing thrombus formation and reducing risk of heart attack and stroke. The cholesterol lowering medications segment is also anticipated to witness significant growth during the forecast period due to increasing awareness about managing cholesterol levels for prevention of cardiovascular diseases (CVDs). In terms of application, retail pharmacies are estimated to account for a major share of the global Atherosclerosis Drug Market in 2018. This can be attributedtothe growing trendof self-medicationand rising demandfor prescription drugs over OTC drugs.
Product Definition:
The term atherosclerosis refers to a group of diseases that involve the build-up of plaque in the arteries. Atherosclerosis drugs are used to help prevent this from happening.
Anti-platelet Medications:
Anti-platelet Medications, it's usage.
The anti-platelet medications are used to prevent blood clots from dissolving. They work by decreasing platelets aggregation or tendency to clot. The most commonly used anti-platelet medication is aspirin; however, there are other drugs as well that have different mechanisms of actions.
Cholesterol Lowering Medications:
The global cholesterol lowering medications and it’s usage in atherosclerosis drug market size was valued at USD 21,oxygenator,during the forecast period. The growing prevalence of cardiovascular diseases globally is expected to be a high impact rendering driver for this market. According to the American Heart Association estimates, more than 87 million people in America suffer from some form of cardiovascular disease.
Application Insights:
The retail pharmacies segment held the largest share of over 60.0% in 2017. This is attributed to the availability of a wider product portfolio in comparison with other regions and increasing awareness about cholesterol-related diseases among consumers, especially in developed countries such as North America and Europe. The hospital pharmacy segment is expected to witness lucrative growth during the forecast period owing to an increase in prevalence of chronic diseases, especially diabetes mellitus which requires regular medication practices. Furthermore, growing investments by governments for developing advanced healthcare facilities along with rising number of hospitals are anticipated to boost industry growth over the forecast period.
Online pharmacies also hold promising potential due to various benefits offered including convenience and accessibility along with security from fraud prevention systems embedded within these platforms which assist customers/users without any intermediaries between them and pharma companies resulting into lower transaction costs for both sides involved (pharma company & customer).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of cardiovascular diseases, rising geriatric population, and availability of effective treatment methods. Moreover, high adoption of new technologies by manufacturers and enhanced R&D capabilities are also contributing towards growth in this region.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to growing target population base with respect to atherosclerosis diagnosis coupled with rapidly improving healthcare infrastructure & affordability in countries such as India and China. Furthermore, increasing awareness about early diagnosis among patients will drive regional market growth during the estimated time span from 2018-2030 (Ref: 1).
The key players operating in this industry are Pfizer Inc.; Merck & Co., Inc.
Growth Factors:
- Increasing prevalence of atherosclerosis and its risk factors such as obesity, hypertension, and diabetes.
- Growing geriatric population susceptible to atherosclerosis.
- Rising demand for novel and more effective therapies for the treatment of atherosclerosis.
- Technological advancements in the field of drug discovery and development that are likely to result in the introduction of new drugs for the treatment of atherosclerosis over the next few years. 5) increasing healthcare expenditure by governments and private players worldwide that is expected to boost growth prospects for Atherosclerosis Drug market during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Atherosclerosis Drug Market Research Report
By Type
Anti-platelet Medications, Cholesterol Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Other, Atherosclerosis Dru
By Application
Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
By Companies
GlaxoSmithKline, Sanofi, F. Hoffmann-La Roche, Bayer, Novartis, Merck & Co, Janssen Pharmaceuticals, Mylan, Amgen Inc, Pfizer, Atherosclerosis Dru
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Atherosclerosis Drug Market Report Segments:
The global Atherosclerosis Drug market is segmented on the basis of:
Types
Anti-platelet Medications, Cholesterol Lowering Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Other, Atherosclerosis Dru
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-La Roche
- Bayer
- Novartis
- Merck & Co
- Janssen Pharmaceuticals
- Mylan
- Amgen Inc
- Pfizer
- Atherosclerosis Dru
Highlights of The Atherosclerosis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-platelet Medications
- Cholesterol Lowering Medications
- Fibric Acid and Omega-3 Fatty Acid Derivatives
- Other
- Atherosclerosis Dru
- By Application:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Atherosclerosis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Atherosclerosis drug is a medication used to treat atherosclerosis. Atherosclerosis is a condition in which fatty deposits build up on the walls of arteries, causing them to narrow and eventually become blocked. A number of different medications are available to treat atherosclerosis, but each has its own set of side effects and risks.
Some of the major companies in the atherosclerosis drug market are GlaxoSmithKline, Sanofi, F. Hoffmann-La Roche, Bayer, Novartis, Merck & Co, Janssen Pharmaceuticals, Mylan, Amgen Inc, Pfizer, Atherosclerosis Dru.
The atherosclerosis drug market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Atherosclerosis Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Atherosclerosis Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Atherosclerosis Drug Market - Supply Chain
4.5. Global Atherosclerosis Drug Market Forecast
4.5.1. Atherosclerosis Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Atherosclerosis Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Atherosclerosis Drug Market Absolute $ Opportunity
5. Global Atherosclerosis Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Atherosclerosis Drug Market Size and Volume Forecast by Type
5.3.1. Anti-platelet Medications
5.3.2. Cholesterol Lowering Medications
5.3.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
5.3.4. Other
5.3.5. Atherosclerosis Dru
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Atherosclerosis Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Atherosclerosis Drug Market Size and Volume Forecast by Application
6.3.1. Retail Pharmacies
6.3.2. Hospital Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Atherosclerosis Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Atherosclerosis Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Atherosclerosis Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Atherosclerosis Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Atherosclerosis Drug Demand Share Forecast, 2019-2026
9. North America Atherosclerosis Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Atherosclerosis Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Atherosclerosis Drug Market Size and Volume Forecast by Application
9.4.1. Retail Pharmacies
9.4.2. Hospital Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Atherosclerosis Drug Market Size and Volume Forecast by Type
9.7.1. Anti-platelet Medications
9.7.2. Cholesterol Lowering Medications
9.7.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
9.7.4. Other
9.7.5. Atherosclerosis Dru
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Atherosclerosis Drug Demand Share Forecast, 2019-2026
10. Latin America Atherosclerosis Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Atherosclerosis Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Atherosclerosis Drug Market Size and Volume Forecast by Application
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Atherosclerosis Drug Market Size and Volume Forecast by Type
10.7.1. Anti-platelet Medications
10.7.2. Cholesterol Lowering Medications
10.7.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
10.7.4. Other
10.7.5. Atherosclerosis Dru
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Atherosclerosis Drug Demand Share Forecast, 2019-2026
11. Europe Atherosclerosis Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Atherosclerosis Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Atherosclerosis Drug Market Size and Volume Forecast by Application
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Atherosclerosis Drug Market Size and Volume Forecast by Type
11.7.1. Anti-platelet Medications
11.7.2. Cholesterol Lowering Medications
11.7.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
11.7.4. Other
11.7.5. Atherosclerosis Dru
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Atherosclerosis Drug Demand Share, 2019-2026
12. Asia Pacific Atherosclerosis Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Atherosclerosis Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Atherosclerosis Drug Market Size and Volume Forecast by Application
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Atherosclerosis Drug Market Size and Volume Forecast by Type
12.7.1. Anti-platelet Medications
12.7.2. Cholesterol Lowering Medications
12.7.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
12.7.4. Other
12.7.5. Atherosclerosis Dru
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Atherosclerosis Drug Demand Share, 2019-2026
13. Middle East & Africa Atherosclerosis Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Atherosclerosis Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Atherosclerosis Drug Market Size and Volume Forecast by Application
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Atherosclerosis Drug Market Size and Volume Forecast by Type
13.7.1. Anti-platelet Medications
13.7.2. Cholesterol Lowering Medications
13.7.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
13.7.4. Other
13.7.5. Atherosclerosis Dru
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Atherosclerosis Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Atherosclerosis Drug Market: Market Share Analysis
14.2. Atherosclerosis Drug Distributors and Customers
14.3. Atherosclerosis Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffmann-La Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bayer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck & Co
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Janssen Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Amgen Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pfizer
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Atherosclerosis Dru
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
